Diurnal and its development partner, Phoqus plc, have developed a tablet that utilises Diurnal’s ‘delayed and sustained release therapy’ patent to deliver hydrocortisone in a manner that mimics the normal physiological circadian rhythm. This clearly defined rhythm, with high levels in the morning and low levels at night, is lost in patients with adrenal insufficiency. The product, which is entering Phase III clinical studies, has received two related Orphan Medicinal Product designations from the European Medicines Agency, which affords ten years of market exclusivity after the grant of a marketing authorisation in Europe.